CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Allergen Testing (serum and skin) coverage

Defines medical necessity, coverage limitations, and reimbursement stance for in‑vitro specific and total IgE testing, skin testing contraindications, and several proprietary/experimental allergy tests for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyAllergen Testing (serum and skin) coverage

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSelect and document targeted allergens based on history, exam, and environment; limit specific IgE testing to up to 20 allergen-specific antibodies per year when clinically indicated.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 20allergen-specific antibodies covered per year

1month exclusion after anaphylactic event for skin testing

50M+Americans affected by allergies (context)

CLIA-regLDT regulatory status

85%pooled sensitivity of SPT (avg)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Allergen Testing

Medically necessary / Covered indications

Covered when any of the following are met:

Specific IgE in‑vitro testing: Specific IgE in‑vitro allergy testing meets coverage criteria when used (a) in lieu of skin testing for an initial allergy screen; (b) when skin testing is contraindicated; or (c) when confirmation of sensitivity would impact treatment decisions for individuals whose skin test results are inconsistent with history of anaphylactic or other severe reaction.up to 20 allergen-specific antibodies per year when limited to allergens chosen based on history, exam, and environment

Document clinical rationale and selection of allergens.

Total IgE testing: In‑vitro testing for total serum IgE meets coverage criteria when (a) individuals have moderate to severe asthma and are being considered for omalizumab (Xolair) therapy, or (b) individuals are suspected of having allergic bronchopulmonary aspergillosis.

Document indication (e.g., consideration for Xolair).

Monitoring food allergy resolution in pediatrics: Annual re‑testing for the same food allergen(s) meets coverage criteria to monitor for allergy resolution in children and adolescents with an initial positive food allergen result(s).annual

Applies to children and adolescents only.

Not medically necessary / Experimental

Not covered or considered experimental due to insufficient evidence:

Explicitly not covered tests: The antigen leukocyte antibody test (ALCAT); in‑vitro testing of IgG, IgA, IgM, and/or IgD for evaluation of suspected allergy; basophil activation flow cytometry testing (BAT); in‑vitro allergen testing using bead‑based epitope assays (e.g., VeriMAP Peanut Dx/VeriMAP Peanut Sensitivity); and qualitative specific IgE multi‑allergen screens that do not identify a specific allergen do not meet coverage criteria.

Listed as not meeting coverage criteria in policy.

Medically necessary testing

Covered when testing is clinically indicated and targeted to suspected allergens:

General indication: Testing (skin prick test or serum specific IgE) is appropriate when history and physical examination suggest IgE‑mediated allergy and when test selection is guided by patient‑specific factors (age, exposures, geographic region, occupation, and presenting symptoms).

Selection should be history‑directed per AAAAI/ACAAI and JTFPP guidance.

Special circumstances favoring in‑vitro testing: Use specific IgE immunoassays instead of skin testing for patients with widespread skin disease, patients receiving skin‑suppressive therapy or antihistamines that cannot be stopped, uncooperative patients, or when skin testing poses an unusually high risk of anaphylaxis.

Per AAAAI/ACAAI practice parameters.

Peanut evaluation and component testing: For suspected peanut allergy, perform SPT or sIgE when pretest probability is high. Consider Ara h 2 component testing when a single diagnostic test is desired because of superior diagnostic accuracy, recognizing component testing may have lower sensitivity than whole‑extract tests.

Per AAAAI 2020 peanut practice parameter update.

Indications and appropriate use

Tests are supported when clinical history and patient circumstances warrant them; selection depends on the suspected condition and patient factors.

SPT or sIgE for suspected IgE‑mediated conditions: Perform skin prick testing or serum sIgE to confirm allergen sensitization when the clinical history is consistent with IgE‑mediated conditions (for example: asthma, rhinitis/rhinosinusitis, conjunctivitis, eczema with high suspicion of IgE sensitization, suspected food allergy with a relevant history, suspected drug allergy, hymenoptera venom allergy, occupational exposures, and select cases of chronic urticaria).

SPT is often first‑line for aeroallergens; use sIgE when SPT is contraindicated or not feasible.

When SPT is not indicated: Do not perform SPT routinely for suspected food intolerance, chronic urticaria without allergic features, non‑specific food‑associated symptoms, screening without clinical symptoms, non‑specific cutaneous rashes without atopic features, or to assess immunotherapy effectiveness (except where clinically indicated). Use history‑guided sIgE or other appropriate approaches instead.

WAO and guideline statements list multiple non‑indications for routine SPT.

Component diagnostics and BAT use: Consider component‑resolved molecular diagnostics to refine risk assessment and to evaluate unclear triggers; consider BAT when first‑line tests are inconclusive or to monitor response to immunotherapy, recognizing evidence and standardization vary.

Panels or proprietary assays that lack established analytical or clinical validity and utility are excluded from coverage. Examples include broad IgG/IgE food panels and microarray-style panels offered by some vendors, as well as bead-based epitope assays such as VeriMAP™ Peanut Dx and proprietary tests marketed without sufficient peer-reviewed evidence. These tests are not considered medically necessary when they are offered as indiscriminate multi-analyte screens rather than targeted assays selected based on clinical history and examination.

When such proprietary or large-panel tests are proposed, providers should instead document the clinical rationale for targeted testing (selection of specific allergens based on history, exam, and environment) and use validated, focused sIgE or skin testing approaches that meet coverage criteria.

In‑vitro measurement of immunoglobulin G (IgG) and IgG subclass antibodies for evaluation of suspected food allergy does not meet coverage criteria and is considered not medically necessary. The policy states that in‑vitro testing of IgG, IgA, IgM, and/or IgD for the assessment of allergy lacks sufficient evidence correlating these results with clinical allergy and therefore should not be performed for diagnosis of food allergy.

Clinicians should rely on history-directed sIgE testing and/or skin prick testing, and reserve other immunologic assays for research contexts or validated indications supported by the literature.

Skin prick testing (SPT) is not routinely indicated for several non-IgE-mediated presentations. Specifically, SPT should not be performed routinely for suspected food intolerance (e.g., IBS), chronic urticaria without allergic features in the history, non-specific food-associated symptoms (additives/preservatives), screening in the absence of clinical symptoms, non-specific cutaneous rashes without atopic features, weight-loss claims, migraine (except hormone hypersensitivity), or chronic fatigue syndrome.

When SPT is indicated, selection should be driven by an allergy-focused history and local prevalence; sIgE or other approaches are preferred when SPT is contraindicated (widespread skin disease, interfering therapies) or not feasible.

Laboratory-developed tests (LDTs) are regulated under CLIA as high-complexity, in‑house validated assays and are generally not FDA‑cleared or approved. FDA clearance or approval is not a prerequisite for clinical use of an LDT; however, laboratories must validate such tests and perform them in compliance with CLIA requirements to support clinical use and any coverage determinations.

The literature describes several diagnostic techniques that remain unproven or insufficiently standardized for routine clinical use. Examples include various microarray or epitope-mapping approaches and other emerging modalities discussed in review articles and specialty reports; peer-reviewed evidence establishing consistent analytical validity, clinical validity, and utility is required before these methods are accepted as standard of care.

Providers should refer to the cited literature and guideline statements when considering novel or less-established diagnostic techniques and document justification when such methods are used in exceptional cases.

Routine re-testing for the same allergens in the absence of a new clinical presentation does not meet coverage criteria and may be denied. An exception is annual re‑testing to monitor allergy resolution in children and adolescents where this specific indication is allowed; otherwise, repeat testing requires clinical justification based on a change in history or signs/symptoms.

Routine measurement of total serum IgE for the purpose of diagnosing food allergy is discouraged because of its low positive predictive value. Total IgE testing is supported when indicated for other clinical reasons (for example, to determine pre-treatment levels before initiating omalizumab/Xolair for moderate to severe asthma) but should not be used routinely to diagnose food allergy.

Routine use of broad multiallergen food panels or indiscriminate sIgE screening (especially tests that include foods other than peanut or that do not identify specific allergens) is discouraged due to poor positive predictive value and the potential for misinterpretation, overdiagnosis, and unnecessary dietary restriction.

Testing should be targeted to foods implicated by history and clinical context; for peanut specifically, guideline-based focused testing (sIgE, SPT, and, when appropriate, component testing such as Ara h 2) is preferred over broad screening panels.

Codes and Billing Information

Applicable CPT/HCPCS/PLA codes listed in sectionmixed

82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each.
82785	Gammaglobulin (immunoglobulin); IgE.
82787	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (e.g., IgG1, 2, 3, or 4), each.
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
86001	Allergen specific IgG quantitative or semiquantitative, each allergen.
86003	Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each.
86005	Allergen specific IgE; qualitative, multiallergen screen (e.g., disk, sponge, card).
86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each.
88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker.
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker.

1–10 of 12

1/2

Procedure code noticeneutral

CPT® is a registered trademark of the AMA; procedure codes included as general reference and may not be all-inclusive.

sIgE follow-up threshold (example)

Example follow-up sIgE level>20-50 kUA/L — level mentioned where less frequent retesting may be acceptable for food allergies

Coverage limit contextSpecific IgE testing is limited to allergens selected based on history, exam, and environment (up to 20 allergen-specific antibodies per year)

Retesting guidanceRoutine re‑testing for the same allergens without a new clinical presentation does not meet coverage criteria

Pediatric monitoring noteAnnual re‑testing for the same food allergen(s) is covered to monitor resolution in children/adolescents with prior positive results

Basophil reactivity/sensitivity thresholds

CD63 reactivity threshold

Provider Actions, Documentation, and Authorization

Denial Risk

Excluded / Experimental Tests

The following tests and uses are excluded as experimental or not covered due to insufficient evidence supporting clinical benefit: the antigen leukocyte antibody test (ALCAT); in‑vitro testing of IgG, IgA, IgM, and/or IgD for evaluation of suspected allergy; basophil activation flow cytometry testing (BAT) when used as a routine diagnostic (see limited specialist contexts in evidence); in‑vitro allergen testing using bead‑based epitope assays (e.g., VeriMAP Peanut Dx); and qualitative multi‑allergen specific IgE screens that do not identify specific allergens. These tests DO NOT MEET COVERAGE CRITERIA and may be denied if billed without prior approval and appropriate clinical justification.

ALCAT: not covered
IgG/IgA/IgM/IgD in‑vitro testing: not covered
BAT: not covered for routine use (may be considered in specialized contexts by specialists)
Bead‑based epitope assays (e.g., VeriMAP): not covered
Qualitative multiallergen IgE screens without specific allergen identification: not covered

Background and Context

Most clinically significant immediate-type allergies are mediated by immunoglobulin E (IgE; Type I hypersensitivity), whereas delayed reactions such as allergic contact dermatitis are mediated by T cells (Type IV hypersensitivity). Accurate diagnosis of IgE-mediated allergy requires (1) identification of a plausible allergen exposure in the patient’s history, (2) demonstration of specific IgE sensitization by skin testing or serum sIgE, and (3) correlation of test results with the clinical presentation or oral food challenge when necessary.

Total serum IgE has limited diagnostic utility for food allergy but is clinically useful in specific scenarios such as informing dosing decisions for omalizumab in moderate to severe asthma. Patch testing remains the gold standard for T-cell mediated contact dermatitis and should be used when that condition is suspected.

Definitions and Test Descriptions

sIgE / s-IgE definition

DefinitionSpecific immunoglobulin E (s-IgE) — immunoglobulin E measured in serum to detect sensitization to particular allergens

Measurement contextUsed in vitro when skin testing is contraindicated or not feasible; assists in confirming allergen sensitization

Relation to diagnosissIgE results should be interpreted with clinical history; testing should be focused on suspected allergens

ALCAT definition

ALCAT — full nameAntigen Leukocyte Antibody Test — a leukocyte stimulation assay offered commercially

Clinical validityResults have lacked reproducibility and do not correlate reliably with clinical evidence of allergy

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyAllergen Testing (serum and skin) coverage

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSelect and document targeted allergens based on history, exam, and environment; limit specific IgE testing to up to 20 allergen-specific antibodies per year when clinically indicated.

SourceLink

On This Page

Use of BAT: Basophil activation testing (BAT) may be considered as an adjunct when SPT and sIgE (including component testing) are equivocal, particularly to reduce the need for oral food challenge and to assess reaction severity/threshold, while acknowledging current limitations in standardization.

Supported by studies showing high BAT accuracy but limited standardization.

Patch testing indication: Patch testing is indicated and is the gold standard for identifying allergic contact dermatitis and should be used when contact allergy is suspected per JTFPP recommendations.

Use per JTFPP practice parameter statements.

Apply these tests in selected circumstances with documented rationale.

Pediatric evaluation prior to peanut introduction: For infants at high risk for peanut allergy (severe eczema and/or egg allergy), strongly consider peanut sIgE and/or SPT before introducing peanut; avoid broad multiallergen food panels due to poor positive predictive value and risk of unnecessary dietary restriction.

Based on NIAID, AAAAI, and AAP guidance.

Safety and competency prerequisites: All testing should be performed only by healthcare professionals with appropriate competency to select, perform, and interpret tests; skin prick testing in children must be done where facilities to manage anaphylaxis are available.

Per NICE and international consensus statements.

CD63 peanut/anti-IgE ratio ≥ 1.3 is associated with increased risk of severe reactions (relative risk 3.4)

CD-sens sensitivity thresholdCD-sens ≥ 84 associated with increased likelihood of reacting to ≤0.1 g peanut protein (relative risk 1.9)

Clinical useBasophil reactivity correlates with severity and basophil sensitivity correlates with threshold of reaction during oral food challenges

Application noteBAT parameters can be used to estimate severity and reaction threshold but require appropriate interpretation and validation

Documentation Required

Government Policy Precedence

When there is a conflict between this policy and an applicable government policy (for example, Local Coverage Determinations, National Coverage Determinations for Medicare, or state Medicaid rules), the applicable government policy takes precedence and will be used to make coverage determinations. Providers should consult the Medicare Coverage Database and the applicable state Medicaid website for the most current guidance.

Follow LCDs and NCDs where applicable
State Medicaid policies supersede when applicable
Medicare coverage searchable at http://www.cms.gov/medicarecoverage-database/search.aspx

Documentation Required

Total IgE: Indication and Documentation Requirements

Document the clinical indication for measuring total serum IgE when used for coverage‑approved purposes. Acceptable indications include: assessment of individuals with moderate to severe asthma being considered for omalizumab (Xolair) where pre‑treatment total IgE and body weight determine dosing, and evaluation of suspected allergic bronchopulmonary aspergillosis. Do not use total IgE as a routine diagnostic for food allergy. Record the clinical history, relevant signs/symptoms, diagnostic question being asked, and how the total IgE result will affect management (e.g., initiation/dosing of Xolair). Note that total IgE levels rise during Xolair treatment and re‑testing during therapy should not be used for dose determination.

Indications acceptable for total IgE: pre‑Xolair dosing for moderate–severe asthma; suspected allergic bronchopulmonary aspergillosis
Document: allergy‑focused clinical history, reason for test, how result will change management
Do not use total IgE routinely for food allergy diagnosis
Do not re‑test total IgE during Xolair to determine dose

Documentation Required

Provider Actions and Documentation Expectations

Providers must follow these general provider‑action requirements when ordering allergy testing: select targeted tests based on an allergy‑focused clinical history and examination; document the rationale for test selection and how results will impact patient management; ensure testing is performed by or interpreted with appropriate competencies; and recognize that routine re‑testing for the same allergens (absent a new clinical presentation or the limited pediatric food allergy follow‑up exception) is not covered.

Order specific IgE tests targeted to suspected allergens only (limit: up to 20 allergen‑specific antibodies per year when history‑guided)
Include allergy‑focused clinical history and intended management action in documentation
Ensure personnel performing/interpreting tests have appropriate competencies
Routine re‑testing for the same allergens not covered except annual food re‑testing in children/adolescents with initial positive food result

Policy stanceListed in policy as a proprietary/unvalidated test and not meeting coverage criteria

BAT definition (short)

BAT — short descriptionBasophil activation test (BAT) — an ex vivo flow cytometry assay measuring basophil activation after allergen stimulation

Current limitationPromising diagnostic performance but limited by lack of standardization across methods and instruments

Research statusConsidered a research tool by some organizations pending broader standardization and validation

Basophil Activation Test (BAT) — expanded

Expanded definitionBasophil Activation Test (BAT) — a functional in‑vitro flow cytometry assay that measures basophil activation markers (e.g., CD63, CD203c) after allergen stimulation to assess sensitization, reaction threshold, and potential severity

Diagnostic performanceBAT has demonstrated high specificity and comparable sensitivity for food allergy diagnosis in research studies and may reduce need for oral food challenge when used adjunctively

Standardization and limitsWidespread clinical use is limited by variability in methodology and instrument settings; standardization and quality assurance are needed for routine implementation

Clinical roleConsider BAT when SPT and sIgE (including component testing) are equivocal or when skin testing is contraindicated

Component testing (Ara h 2)

Component testing — exampleAra h 2 — Arachis hypogaea 2-specific IgE, a molecular component of peanut with superior diagnostic accuracy

Diagnostic advantagesIgE to Ara h 2 showed the best diagnostic accuracy for peanut compared with whole-extract SPT or sIgE to peanut extract

Use guidanceAra h 2 may be preferred when a single diagnostic test is desired, but it has lower sensitivity and should be used within clinical context

Basophil Activation Test (BAT) — duplicate entry

BAT (duplicate) — core pointBasophil Activation Test measures basophil activation markers (eg, CD63, CD203c) via flow cytometry after allergen stimulation to assess sensitization and may inform severity/threshold

Evidence noteStudies report high diagnostic accuracy for peanut and association of BAT parameters with severity and reaction threshold

Standardization noteLimitations include lack of methodological standardization; quality assurance needed before broader clinical adoption

Precision allergy molecular diagnostics (PAMD@)

PAMD@ definitionPrecision allergy molecular diagnostics (PAMD@) — molecular/component-resolved testing that identifies IgE reactivity to specific allergenic molecules to better assess risk and refine diagnosis

Clinical utilityCan improve diagnostic specificity (e.g., Ara h 2 for peanut) and help define patient-specific sensitization profiles

Use considerationsRecommended for selected circumstances to clarify diagnosis or assess risk, not for routine broad screening

Laboratory-Developed Test (LDT)

LDT — definitionLaboratory-Developed Test (LDT) — a diagnostic test developed and validated within a laboratory and performed in‑house

Regulatory statusLDTs are regulated by CMS under CLIA '88 as high-complexity tests and are not FDA‑cleared or approved for clinical use (FDA clearance not required for clinical use)

Validation requirementLDTs must be validated by the performing laboratory prior to clinical use

Laboratory-developed test (LDT) (duplicate)

LDT (alternate wording)Laboratory‑developed test (LDT) — a diagnostic assay created and performed in‑house by a laboratory; regulated under CLIA as high-complexity and generally not FDA-cleared

Clinical implicationAlthough not FDA‑cleared, LDTs may be clinically used if validated under CLIA by the laboratory

Documentation noteSome specialized or proprietary LDT assays may require laboratory validation documentation when used for clinical decisions

Basophil activation test (BAT) (alternate chunk set)

BAT (alternate supporting chunks)Basophil activation test (BAT) — laboratory flow cytometry assay measuring basophil activation to discriminate allergy from tolerance in food‑sensitized individuals

Research evidenceMultiple studies (e.g., Santos et al.) demonstrate BAT discriminates allergy vs tolerance and reflects severity/threshold

Implementation caveatTransition to routine clinical practice depends on standardization, automation, and multicenter validation

Skin prick test (SPT)

SPT — definitionSkin prick test (SPT) — an in vivo diagnostic test for immediate‑type (IgE‑mediated) hypersensitivity using standardized extracts applied to the skin

Interpretation caveatResults vary by operator and device and must be interpreted alongside specific IgE results and clinical history

Clinical roleSPT is often first‑line for detection of IgE antibodies due to speed, simplicity, and low cost; perform with appropriate facilities and competencies (anaphylaxis management)